Cargando…

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

BACKGROUND: Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-metastasis protein, previously identified as a relevant PDAC antigen that is ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Victoria M., Blair, Alex B., Lauer, Peter, Foley, Kelly, Che, Xu, Soares, Kevin, Xia, Tao, Muth, Stephen T., Kleponis, Jennifer, Armstrong, Todd D., Wolfgang, Christopher L., Jaffee, Elizabeth M., Brockstedt, Dirk, Zheng, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529991/ https://www.ncbi.nlm.nih.gov/pubmed/31113479 http://dx.doi.org/10.1186/s40425-019-0601-5

Ejemplares similares

Development of mutome-specific personalized vaccines for pancreatic cancer
por: Lutz, Eric, et al.
Publicado: (2013)

Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors
por: Brockstedt, Dirk G, et al.
Publicado: (2013)

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
por: Mkrtichyan, Mikayel, et al.
Publicado: (2013)

Modified STING-activating cyclic dinucleotide derivatives significantly enhance the anti-tumor activity of therapeutic vaccines
por: Leong, Meredith, et al.
Publicado: (2013)

Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer
por: Murphy, Adrian G., et al.
Publicado: (2017)

Mice Lacking the Type I Interferon Receptor Are Resistant to Listeria monocytogenes
por: Auerbuch, Victoria, et al.
Publicado: (2004)

A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy
por: Bigelow, Emma, et al.
Publicado: (2022)

A Potent and Effective Suicidal Listeria Vaccine Platform
por: Hanson, William G., et al.
Publicado: (2019)

Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis
por: Lizotte, Patrick H, et al.
Publicado: (2014)

Tumor-Associated Antigen Expressing Listeria monocytogenes Induces Effective Primary and Memory T-Cell Responses Against Hepatic Colorectal Cancer Metastases
por: Olino, Kelly, et al.
Publicado: (2011)

Enhanced Virus-Specific CD8(+) T Cell Responses by Listeria monocytogenes-Infected Dendritic Cells in the Context of Tim-3 Blockade
por: Ma, Cheng J., et al.
Publicado: (2014)

Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction
por: Shojaie, Mohammad, et al.
Publicado: (2009)

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer
por: Drake, Charles G., et al.
Publicado: (2021)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Interplay between CD8α(+) Dendritic Cells and Monocytes in Response to Listeria monocytogenes Infection Attenuates T Cell Responses
por: Kapadia, Dilnawaz, et al.
Publicado: (2011)

Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma
por: Oladejo, Mariam, et al.
Publicado: (2022)

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy
por: Shrimali, Rajeev, et al.
Publicado: (2017)

Concomitant appearance of anti-cardiolipin, anti-β(2)-glycoprotein I, anti-prothrombin and anti-annexin V antibodies
por: Cucnik, S, et al.
Publicado: (2004)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
por: Cowles, Sarah C., et al.
Publicado: (2022)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

Anti-Phosphatidylserine, Anti-Prothrombin, and Anti-Annexin V Autoantibodies in Antiphospholipid Syndrome: A Real-Life Study
por: Roselli, Daniele, et al.
Publicado: (2023)

Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model
por: Lim, Joanne YH, et al.
Publicado: (2014)

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2019)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer
por: Nakayama, Yuko, et al.
Publicado: (2019)

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
por: Manson, Guillaume, et al.
Publicado: (2019)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

The involvement of anti-inflammatory protein, Annexin A1, in ocular toxoplasmosis
por: Mimura, Kallyne K., et al.
Publicado: (2012)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Rational Laboratory Diagnostics of Antiphospholipid Antibodies: Anti-Cardiolipin, Anti-β2-Glycoprotein I, Anti-Prothrombin and Anti-Annexin V Antibodies
por: Borut, Bozic, et al.
Publicado: (2010)

Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load
por: da Fonseca-Martins, Alessandra M., et al.
Publicado: (2019)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
por: Wu, Jinyao, et al.
Publicado: (2023)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
por: Zhang, Hao, et al.
Publicado: (2023)

Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer
por: Saung, May Tun, et al.
Publicado: (2018)

Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer
por: Nair, Nitya, et al.
Publicado: (2015)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dsebuqj5u69h27j95pqrthh0gi